Free Republic

An alarming admission was found near the bottom of a recent New York Times article about pharmaceutical giant Merck’s new Covid drug molnupiravir. Approved by the FDA two weeks ago, the drug was studied on isolated hamster cells for 32 days before being given the green light. While the FDA narrowly voted to recommend emergency use authorization for the drug, France’s National Authority of Health on Friday cited the pill’s own lack of efficacy as it ruled it will not be used in the European nation. According to the NYT report, “A team of researchers at the University of North...

A total of 35,691 v-safe participants 16 to 54 years of age identified as pregnant. Injection-site pain was reported more frequently among pregnant persons than among nonpregnant women, whereas headache, myalgia, chills, and fever were reported less frequently. Among 3958 participants enrolled in the v-safe pregnancy registry, 827 had a completed pregnancy, of which 115 (13.9%) resulted in a pregnancy loss and 712 (86.1%) resulted in a live birth (mostly among participants with vaccination in the third trimester). Adverse neonatal outcomes included preterm birth (in 9.4%) and small size for gestational age (in 3.2%); no neonatal deaths were reported. Although...